Provided are: a method for producing fluorenylidene diallylphenols represented by formula (1), the method including a reaction step for reacting fluorenones represented by formula (2) and allylphenols represented by formula (3) in the presence of an acid catalyst, excluding compounds having mercapto groups, the amount of acid catalyst being 0.001-20 mol per mol of compound represented by formula (2); and fluorenylidene diallylphenols represented by formula (4).

##STR00001##

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

The present invention relates to compounds of formula (I): ##STR00001## including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof:

##STR00001##

wherein each symbol is as defined in the specification.

The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof:

##STR00001##

wherein each symbol is as defined in the specification.

A method of extracting cannabidiol from hemp. The method may include the following steps: performing grinding and drying on an extraction part of the hemp to obtain crude drug powder; extracting the crude drug powder with 30-100% (V/V) ethanol to obtain an extracting solution; concentrating the extracting solution to obtain an extractum; performing water precipitation on the extractum to remove impurities, thereby obtaining a water precipitation solution; centrifuging the water precipitation solution, and adding 10-100% (V/V) ethanol to dissolve the obtained precipitate, thereby obtaining a precipitate alcohol solution; performing column chromatography on the precipitate alcohol solution; concentrating the eluate obtained by elution after column chromatography, and adding ethanol for supersaturation and dissolution to obtain a crystal; adding purified water or ethanol to wash the crystal, thereby obtaining a primary product; and uniformly mixing the primary product with purified water, and drying to obtain the cannabidiol.

A method of extracting cannabidiol from hemp. The method may include the following steps: performing grinding and drying on an extraction part of the hemp to obtain crude drug powder; extracting the crude drug powder with 30-100% (V/V) ethanol to obtain an extracting solution; concentrating the extracting solution to obtain an extractum; performing water precipitation on the extractum to remove impurities, thereby obtaining a water precipitation solution; centrifuging the water precipitation solution, and adding 10-100% (V/V) ethanol to dissolve the obtained precipitate, thereby obtaining a precipitate alcohol solution; performing column chromatography on the precipitate alcohol solution; concentrating the eluate obtained by elution after column chromatography, and adding ethanol for supersaturation and dissolution to obtain a crystal; adding purified water or ethanol to wash the crystal, thereby obtaining a primary product; and uniformly mixing the primary product with purified water, and drying to obtain the cannabidiol.